SLP - Simulations Plus Inc
Executive Summary
Simulations Plus Inc is a US-listed healthcare technology company that develops modelling and simulation software, together with supporting data services, for pharmaceutical and biotechnology customers. Its flagship platform, GastroPlus, is a physiologically-based pharmacokinetic (PBPK) simulation tool used by drug developers and regulatory scientists to predict absorption, distribution, metabolism and excretion (ADME) profiles, and the company also provides clinical pharmacology and regulatory consulting services. The group is positioned as a long-standing, specialised vendor in a niche corner of the drug development software stack, with a multi-year relationship with the US FDA and a footprint across both large pharmaceutical and emerging biotech clients.
The investment case rests on the announced cash acquisition of Simulations Plus at USD18.50 per share, which establishes a hard ceiling on upside at current levels and a floor under the equity while regulatory clearance and closing are pending. The key near-term catalyst is the closing of that transaction, the timing of which is not confirmed in the available research and is therefore unconfirmed. The principal risk is that cybersecurity and data-protection disclosures already on file introduce execution uncertainty that could delay or jeopardise closing, eroding the merger arbitrage-style premium currently embedded in the share price. Adjacent to the deal, the most recent quarterly result (Q2 fiscal 2026, reported in April 2026) demonstrated revenue growth and an earnings beat, and a strategic collaboration with NVIDIA announced in May 2026 adds optionality on the underlying franchise if the deal does not complete.
OPPORTUNISTIC BUY. Conviction Score: 59/100. The view would be upgraded to a more confident long if closing of the Altaris transaction is confirmed on a clear timeline with minimal conditions, and would be downgraded if the cybersecurity disclosure crystallises into a material incident or if the transaction is restructured or terminated.
Business Model
Simulations Plus generates revenue across two complementary divisions: software and services. The software segment is built around licensed platforms such as GastroPlus, which is sold to pharmaceutical and biotechnology customers through recurring licence and maintenance contracts; this segment is the higher-margin and more predictable component of the mix. The services segment provides clinical pharmacology, regulatory consulting, and data analytics work, including quantitative systems pharmacology and modelling support for trial design and regulatory submissions; this segment is more project-based and tends to be tied to milestone delivery on individual client programmes.
Customers are predominantly large and mid-sized pharmaceutical and biotechnology companies, supplemented by regulatory and academic clients, with the US FDA historically a notable reference user of the GastroPlus platform. The competitive moat is built on scientific credibility accumulated over decades, deep embedding within regulatory workflows, and the high switching cost of replacing validated PBPK models that have already been used in approved submissions. The franchise is, however, narrow: revenue is concentrated in a specialised corner of the drug development toolkit, and customer concentration metrics in the available research are not detailed, so the exact concentration of the top clients is unconfirmed.
The Q2 fiscal 2026 print (reported in April 2026) showed total revenue of approximately USD24.3 million, up 8% year on year, with software revenue up 9% and services also growing, and an EPS of USD0.35 against expectations of USD0.27. The company guided Q3 fiscal 2026 revenue to between USD20 million and USD22 million with adjusted EBITDA margins in the 27% - 33% range, indicating some lumpiness but still healthy underlying software gross margins. The traditional appeal of the model has been high operating leverage from a fixed cost base of engineers and scientists, although in the current deal and valuation context the day-to-day operating story is secondary to the pending acquisition.
Financial Snapshot
Recent Catalysts
[Q2 fiscal 2026, reported April 2026] - Simulations Plus reported Q2 fiscal 2026 revenue of approximately USD24.3 million, up 8% year on year, with EPS of USD0.35 versus consensus of USD0.27, and raised its software growth trajectory. The result exceeded the company's own top-line guidance and signalled a return to operating profit growth. Source: The Motley Fool (Q2 2026 earnings transcript) and Quiver Quantitative earnings summary.
[April 2026] - The Q2 fiscal 2026 earnings call set Q3 fiscal 2026 revenue guidance of USD20 million to USD22 million with adjusted EBITDA margins of 27% - 33%, framing near-term expectations for the standalone franchise. Source: Yahoo Finance / Q2 2026 earnings call summary.
[May 2026] - Simulations Plus announced a collaboration with NVIDIA to scale GPU-accelerated, AI-assisted modelling workflows, linking the company's PBPK software base to NVIDIA's compute stack for drug development applications. Source: PharmiWeb press release dated 6 May 2026; GuruFocus news report dated 7 May 2026.
[Unconfirmed timing] - Closing of the previously announced USD18.50 per share cash acquisition by Altaris remains the dominant pending catalyst; the transaction is agreed but closing date, regulatory clearances and any conditions are not specified in the available research and are therefore unconfirmed. Source: Research data derived from public filings commentary (deal terms not cited from a named wire).
Thesis Evaluation
Bull Case (25% weight)
Closing of the USD18.50 per share acquisition completes on schedule with no price revision and limited conditions, allowing shareholders to capture the full cash premium above the current market price of USD18.23. In parallel, the most recent quarter's earnings beat and the NVIDIA collaboration support a healthy underlying franchise, providing reassurance that the deal value is supported by fundamentals. On this outcome, the equity is reasonably expected to migrate to the USD18.50 deal price within the next twelve months, with potential tactical upside if a topping bid were to emerge.
Base Case (50% weight)
The transaction closes at the agreed USD18.50 cash price, but with a longer timeline and modest regulatory friction, during which the share price continues to trade in a narrow band around the current level. Quarterly results continue to track a low double-digit growth profile with software-led margins, supporting the negotiated price. The most likely twelve-month outcome is a trading band around USD18.20, with the deal substantially closing the gap to fair value by the end of the period.
Bear Case (25% weight)
The acquisition is delayed, restructured, or terminated because the cybersecurity and data-protection disclosures on file escalate into a material incident or trigger regulatory pushback. Operating momentum also softens, with Q3 revenue tracking towards the lower end of guidance and software growth decelerating from the 9% level reported in Q2. In that scenario, the merger arb premium evaporates and the equity reverts towards a fundamental valuation below the current price, with a downside target of USD14.00 over the next twelve months.
Key Risks
- Deal break or restructuring: The USD18.50 cash acquisition by Altaris has been agreed but closing is unconfirmed, and any renegotiation, regulatory delay, or termination would remove the merger arbitrage floor currently under the share price. Estimated probability: 30%. Impact: severe.
- Cybersecurity and data protection incident: Filings already disclose cybersecurity and data-protection risks that could disrupt service delivery, trigger regulatory scrutiny, or interfere with the merger timeline. Estimated probability: 20%. Impact: severe.
- Customer concentration and pharma R&D budget cuts: Revenue is concentrated among a small number of large pharmaceutical clients and exposed to the broader biotech funding cycle, which is currently under pressure. Estimated probability: 35%. Impact: moderate.
- Valuation and multiple compression: The trailing P/E of 45.54 offers little valuation cushion beyond the deal price, leaving the shares vulnerable to a derating if the transaction falters or sentiment shifts. Estimated probability: 40%. Impact: moderate.
- Key talent and model continuity: The asset is built on scientific expertise and validated PBPK models, and the loss of senior modellers or failure to integrate with NVIDIA's GPU stack could erode the franchise underpinning the deal price. Estimated probability: 15%. Impact: moderate.
Who Should Own It / Avoid It
Ideal for: Investors who are comfortable with a merger-arb-style exposure and a holding period of typically six to twelve months, ideally with enough flexibility to wait out potential regulatory clearance periods. The position is suited to those with a moderate risk tolerance who can accept binary deal-execution risk in exchange for a defined cash ceiling, and who are not relying on outsized upside from software compounding in the absence of the transaction. A meaningful portion of the return profile is contingent on the deal closing at the agreed price rather than on continued operational outperformance.
Avoid if: Investors looking for a clean, high-growth software compounder with a clear multi-year thesis independent of a single transaction, or those unwilling to accept the legal, regulatory and cybersecurity execution risks that accompany the current deal. Long-term growth investors who require upside materially above the announced cash price should also avoid, as the deal price caps the realistic return profile. Speculative holders seeking a deep-value entry or a turnaround story are not well served by the current risk-reward.
Recommendation
OPPORTUNISTIC BUY - 59/100. The rating reflects a defined catalyst (the USD18.50 cash acquisition) and a tight share price that limits downside while offering modest premium capture, set against a fragile sentiment backdrop and an above-market valuation multiple. An upgrade to a higher-conviction tier would require confirmed closing of the transaction on a clear timeline with minimal conditions, or a topping bid materially above USD18.50. A downgrade would follow any cy At the current price of $18.23 the shares trade at or above our base-case target of $18.20: the base case is fully priced, existing holders should consider trimming, and new positions are not advised above $15.40.
The probability-weighted value across our three scenarios is $17.23, 5% below the current price of $18.23 - the market is currently pricing the shares ahead of our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.
below $15.40 - below this level the upside to the base-case target ($18.20) is at least 2x the downside to the bear case ($14.00), the minimum risk/reward we require before committing new capital.
between $15.40 and $18.20 - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.
above $18.20 - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 25%.
if the thesis is invalidated if the USD18.50 per share cash acquisition by Altaris is terminated, materially restructured below the agreed price, or blocked by regulators, or if cybersecurity and data-protection disclosures escalate into a material incident that disrupts service delivery before closing, regardless of price - the bear target of $14.00 is the backstop, not an arbitrary percentage stop.
Conviction Trend
Latest conviction: 59/100. Trend versus prior report: Down.
| Report date | Conviction |
|---|---|
| 2026-08-01 | 29 |
| 2026-07-25 | 59 |
| 2026-06-28 | 59 |
| 2026-05-30 | 60 |
| 2026-04-27 | 73 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: Public news flow was used, including company earnings releases and the Q2 fiscal 2026 earnings call transcript published by The Motley Fool, earnings summaries on Quiver Quantitative and Yahoo Finance, Markets Daily earnings highlights, a PharmiWeb press release dated 6 May 2026 and a GuruFocus news report dated 7 May 2026 covering the NVIDIA collaboration, and broader market commentary on Yahoo Finance, MarketBeat and Seeking Alpha pages for background colour.
Primary source types: SEC filings and related regulatory disclosures (including the cybersecurity and data-protection risk disclosures referenced in the research data), company press releases and investor relations materials, the Q2 fiscal 2026 earnings call transcript, and third-party financial newswire coverage of the results and the NVIDIA partnership.
Key sources
- Simulations Plus (SLP) Earnings: Latest Report, Earnings Call & Financials
- Simulations Plus (SLP) Stock News & Updates | StockTitan
- Simulations Plus Analyst Ratings and Price Targets | NASDAQ:SLP | Benzinga
- Simulations Plus (SLP) Stock Forecast & Price Target
- Simulations Plus - SLP - Stock Price & News | The Motley Fool
- Simulations Plus, Inc. (SLP) Stock Analysis & Key Metrics (2026)
- Simulations Plus's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile
Data correct as of 2026-08-01.